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Background: Foot ulceration has been reported as the leading cause of hospital admission and amputation in
individuals with diabetes. Diabetes-related foot ulcers require multidisciplinary management and best practice care,
including debridement, offloading, dressings, management of infection, modified footwear and management of
extrinsic factors.
Ulcer debridement is a commonly applied management approach involving removal of non-viable tissue from the
ulcer bed. Different methods of debridement have been reported in the literature including autolytic debridement
via moist wound healing, mechanical debridement utilising wet to dry dressings, theatre based sharps debridement,
biological debridement, non-surgical sharps debridement and newer technology such as low frequency ultrasonic
debridement.
Methods: People with diabetes and a foot ulcer, referred to and treated by the Podiatry Department at Monash
Health and who meet the inclusion criteria will be invited to participate in this randomised controlled trial.
Participants will be randomly and equally allocated to either the non-surgical sharps debridement (control) or low
frequency ultrasonic debridement (intervention) group (n = 322 ulcers/n = 108 participants).
Where participants have more than one ulcer, only the participant will be randomised, not the ulcer. An
investigator not involved in participant recruitment or assessment will be responsible for preparing the random
allocation sequence and envelopes.
Each participant will receive weekly treatment for six months including best practice podiatric management. Each
ulcer will be measured on a weekly basis by calculating total area in centimetres squared. Measurement will be
undertaken by a trained research assistant to ensure outcomes are blinded from the treating podiatrist. Another
member of the research team will assess the final primary outcome.
Discussion: The primary aim of this study is to compare healing rates for diabetes-related foot ulcers using
non-surgical sharps debridement versus low frequency ultrasonic debridement over a six month period. The primary
outcome measure for this study is the proportion of ulcers healed by the six month follow-up period.
Secondary outcomes will include a quality of life measure, assessment of pain and health care resource use
between the two treatment modalities.
Trial registration: Australian New Zealand Clinical Trial Registry: ACTRN12612000490875.
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Background
Diabetes is rapidly increasing in global prevalence, mor-
bidity and mortality. In 2011, 366 million people globally
were living with diabetes, a figure that is equivalent to
8.3% of the world’s adult population. It was estimated
the international community would not reach this figure
until 2030 [1].
In Australia the prevalence of type 2 diabetes has
increased over the past two decades and continues to
rise. Approximately 7% of the Australian population is
thought to have type 2 diabetes and it is estimated that
15% of people with diabetes will develop a foot ulcer
during their lifetime [2]. The consequences of having
diabetes in Australia are significant with over 500,000
hospital admissions and 12,000 deaths attributed to the
condition in 2004 alone [1].
The pathophysiology of foot ulceration is complex and
usually multi-factorial. Peripheral sensory neuropathy,
foot deformity and external trauma, when occurring con-
currently, have been identified as being the three most
common factors that predispose to diabetes-related foot
ulcers (DRFU) [3]. Peripheral arterial disease has also been
shown to lead to the development of ischaemic and
neuro-ischaemic DRFU [2]. Regardless of the true aetio-
logy, the same complications can arise with all DRFU, in-
cluding soft tissue infection, osteomyelitis, tissue necrosis
and failure of ulcer healing, all of which may require hos-
pital admission and potentially result in amputation [4].
Diabetes has been acknowledged to be the most com-
mon cause of non-traumatic lower-limb amputation in
Australia [5]. Furthermore, acute complications affecting
foot ulceration have been reported as the leading cause
of diabetes-related hospital admissions and amputation
[4]. For the years 2004–2005 the Australian Institute of
Health and Welfare reported that DRFU resulted in
9900 acute hospital admissions [4]. In the same period
3400 diabetes-related lower limb amputations were also
reported [2].
More recently it has also been suggested that diabetes-
related lower limb amputations have increased by 30%
between the years 1998 – 2005 [6]. The estimated acute
care cost of a single lower extremity amputation in
Australia could be as much as $26,700 [4]. This figure
does not include costs for rehabilitation, purchase of
orthotics/prosthetics or time lost from work. Recent
economic evaluations of the cost of a lower limb ampu-
tation for a single person found that Australia sits in
third place behind France where such a procedure is es-
timated to cost $46,064 for a single diabetes-related lower
extremity amputation and in Germany the same is esti-
mated at a cost of $31,809 [2]. The cost of amputation
secondary to diabetes complications in the United States
of America is said to range from $20,000 - $60,000 perpatient and similarly does not include the personal, social,
or economic aspects of the patient’s life [7].
None of the costs noted above consider the direct fi-
nancial burden on patients with a DRFU. The ongoing
costs of ulcer management in the community have not
been investigated in the literature to date, however clini-
cians, patients and their families feel the impact of these
costs every day. It has been reported however, that in
one study investigated the quality of life of patients with
DRFU 50% of patients were no longer in work because
of their ulcer. Although treatment was free the costs as-
sociated with travelling to hospital appointments and
buying additional footwear [8] placed an additional fi-
nancial strain on patients.
Given the complications associated with DRFU and
the time these ulcers can take to heal it is not surprising
that patients report a greatly reduced quality of life [9].
It has been found that all quality of life domains can be
adversely impacted primarily because of a reduction in
mobility and the consequent need to adapt activities of
daily living [8]. Additionally it is thought that the pres-
ence of a foot ulcer imposes restrictions on patient par-
ticipation and enjoyment of their usual hobbies mainly
because of mobility difficulties and the requirements for
treatment [9]. This has been shown to have a negative
psychological effect with an increase in patients with de-
pression and a lower satisfaction with their personal lives
[9]. Reviewing and improving ulcer management inter-
ventions that have the potential to result in more effec-
tive and faster healing could have the added benefit of
improving the quality of life of patients with a DRFU.
Debridement has been identified as a leading treat-
ment for management of DRFU [2]. Debridement has
been defined as the removal of devitalised, contaminated
or foreign material from within or adjacent to the ulcer
until surrounding healthy tissue is exposed [10]. It serves
several functions including reduced pressure on the
ulcer base, more thorough inspection to determine true
ulcer depth and size, facilitation of drainage and creation
of an acute ulcer environment [6].
Existing approaches to ulcer debridement can be per-
formed directly by a clinician including theatre-based
sharps debridement (TBSD) also known as surgical exci-
sion and non-surgical sharps debridement (NSSD) or
scalpel debridement in a clinical setting. There are also
various topical products that act as debriding agents.
These have included wet-dry dressings that act as mech-
anical debriding agents, dressings that encourage moist
wound healing and autolytic debridement, biological de-
bridement through use of sterile larvae and also the use
of chemical enzymes [10-13].
Theatre-based sharps debridement has been utilised
for removal of deep necrotic tissue, gangrene and deep
infection [14] but has not been routinely used as part of
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quired more regularly to remove non-viable necrotic tis-
sue from the ulcer surface and is recommended as part
of standard ulcer care [13]. The need for and appropriate
method of ulcer debridement should be determined
based on the clinical presentation [12] and potentially
the clinical skillset and equipment available [13].
Sonoca 185™ (SÖering) was introduced in Australia re-
cently as an alternative method for ulcer debridement.
The technology works by delivering low frequency ul-
trasound, or sound waves, through a constant flow of
saline. Ultrasound results when electrical energy is con-
verted to sound waves at frequencies above the range of
human hearing (20 kHz) with Sonoca 185™ functioning
at 25 kHz [15]. These sound waves can then be transmit-
ted to tissue, via a liquid medium, through a treatment
applicator. It is the non-thermal effects of ultrasound
that have been shown to cause two phenomena at the
ulcer surface; acoustic streaming [15-17] (a steady mech-
anical force delivered in a fluid medium i.e. sterile saline)
and cavitation [15-17] (formation of gas bubbles in the
fluid creating micro-shockwaves). The combined effects
of acoustic streaming and cavitation are thought to alter
cell membrane activity and increase the activity of each
cell [16]. Subsequently this is thought to have three cli-
nical effects: debridement, a bactericidal effect and an
ulcer healing stimulator effect [17-19].
The biological effects indicated through in vitro and
animal studies could contribute to ulcer healing [20].
These effects include stimulation of cellular activity and
protein synthesis, the activation of inflammatory cells
and the production of chemical mediators that activate
fibroblasts and may lead to ulcer healing [15,19,20].
Additionally the mechanical forces produced by the
ultrasound energy at the cellular and molecular levels
may promote ulcer healing by fostering cell division,
angiogenesis, the release of growth factors [20] and stimu-
lating collagen synthesis [15,19]. In vitro data has also
found that low frequency ultrasonic debridement (LFUD)
is effective in reducing microbe count for methicillin-
resistant staphylococcus aureus, vancomycin resistant en-
terococci, pseudomonas and other commonly occurring
bacteria [17,18].
When comparing LFUD with TBSD significant clinical
advantages have been noted in terms of efficacy and safety
for debriding ulcers without deep infection or necrosis.
Successful TBSD is reliant upon the skill of the surgeon
and their ability to distinguish between tissue types. Pro-
cedural risks of TBSD have included pain, bleeding [21],
damage to underlying structures with a resultant loss of
function [13,22], post-surgical infection and the use and
associated risks of general anaesthesia [13].
Comparisons have been made with the use of LFUD
and TBSD in DRFU in a randomised controlled trial,which found a mean healing rate that was 2.5 times fas-
ter using LFUD compared to TBSD over a two week
treatment period. Limitations of this study include the
very short follow-up of only two weeks and the small
sample size (N = 59) [23].
A randomised double-blind controlled trial has com-
pared low-frequency low-intensity ultrasonic debridement
to a sham treatment (saline mist without ultrasound)
in patients with recalcitrant DRFU. Ennis et al. found
that after 12 weeks of treatment 40.7% of patients
who underwent LFUD had healed compared to only
14.3% in the sham treatment group. Whilst this is promi-
sing data the overall numbers of participants were small
(N = 55) [24].
A recent meta-analysis investigating the use of non-
contact low-frequency high-intensity ultrasonic debride-
ment, reported significant improvement compared to
NSSD at three and five months, but no difference at six
months. There were only two studies suitable for the
meta-analysis, one focused on DRFU (N = 40) and the
other venous leg ulcers (N = 76). Again the overall num-
bers were small [16].
Another meta-analysis concluded that non-contact
LFUD is an efficacious treatment for chronic wounds of
varying aetiologies [20]. Despite the quality of the initial
evidence being of low quality suggests that LFUD does
demonstrate short-term clinical benefits when used as
an adjunctive therapy. Recommendations from both
meta-analyses were the same; there is no evidence that
compares LFUD with standard ulcer management. Ad-
ditionally, there is a need for further research using larger
randomised clinical trials of longer period of time.
Given the evidence available it could be expected that
LFUD might be a lower-cost treatment when compared
to TBSD in terms of the cost associated with the actual
treatment itself and potential savings from healing ulcers
faster.
Non-surgical sharps debridement has been considered
the leading comparator to TBSD for several reasons; the
technique is simple and requires the use of basic instru-
ments by a trained professional; it is time efficient and
can be performed in clinic or at the bed-side; does not
require the resources of an operating theatre and has a
lower overall cost.
Evidence on the most appropriate method, frequency
and extent of DRFU debridement is limited and insuffi-
cient to draw any conclusions. The National Evidence-
Based Guidelines for the Prevention, Identification and
Management of Foot Complications in Diabetes recom-
mends that NSSD should be considered first and should
occur repeatedly and as often as required to remove all
non-viable tissue [2]. This recommendation is based on
expert opinion in the absence of evidence pertaining to
DRFU debridement.
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betic foot ulcers notes that while ulcer debridement is
recommended as an effective intervention to assist heal-
ing, no guidelines identify a specific method of debride-
ment. The methods of debridement reviewed included
surgical debridement, topical hydrogels and larval ther-
apy [10]. Neither NSSD nor LFUD were investigated in
the Cochrane Review.
The method of choice for ulcer debridement remains
inconclusive. Evidence suggests that each ulcer needs to
be individually assessed in terms of type, size, position,
appearance, patient pain and tolerance, cost effectiveness
and available expertise and equipment to determine the
most suitable method of debridement [25].
The decision to utilise NSSD as the active control
group in this study was based on the expert opinion in
clinical guidelines and the low cost and easy accessibility
of the treatment for clinicians. The limited data around
LFUD leaves a gap in the evidence that warrants further
investigation. The limited data available on LFUD with
NSSD as standard practice makes this debridement mo-
dality a choice comparator.
It is hypothesised that use of LFUD in the treatment
of DRFU would improve healing rates when compared
with NSSD. There will be four aims within this study.
The primary aim is to determine if there is a difference
in healing rates for DRFU, using NSSD compared to
LFUD. Secondary aims include assessing for differences
in pain during and post-treatment, determining if there
is a difference between the quality of life of participants
who have an ulcer undergoing either method of debride-
ment and if there is a difference in overall costs between
NSSD and LFUD.
This clinical trial will provide important information
in the field of ulcer management; provide a better under-
standing of the efficacy of NSSD and the newer technol-
ogy of LFUD. It will also provide health services with a
better understanding of the financial impacts of both
treatments. This protocol has been designed and re-
ported to ensure it corresponds to the 33 items of the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist [26].
Methods
Study design
This is a randomised controlled trial comparing NSSD
(active control group) and LFUD (treatment group) in
DRFU with a six month follow-up period. A consort flow
chart for the design of this study is presented in Figure 1.
Ethical consideration
Ethical approval for this study has been obtained by
the Monash Health Human Research Ethics Committee
HREC 12101B.Participants and setting
Patients with diabetes and a foot ulcer/s, who are re-
ferred to and treated by the Podiatry Department at
Monash Health, will be invited to participate in this
study. Patients may be inpatients and receiving podiatry
care on the ward or outpatients referred by the patient’s
primary medical care team.
This study is a single centre trial. The average length
of stay for an acute hospital admission in Australia is 6
days [27]. Participants may be recruited during their
hospital admission but it is anticipated they will receive
treatment primarily in the outpatient setting. Inpatients,
however, can receive either treatment if they meet inclu-
sion criteria for this study as both study interventions
can be undertaken by the bedside as well as in an out-
patient clinical setting.
A standard initial podiatric assessment will occur at
baseline including a neurovascular assessment, medical
and surgical history, medications history, diabetes ma-
nagement and control history including glycated hae-
moglobin (Hba1c), footwear assessment, ulcer aetiology,
ulcer duration and previous management. If the partici-
pant meets the inclusion criteria (Table 1) as determined
by the treating podiatrist, the patient will be informed
about the research project and written consent will be
obtained to participate in the study.
Ulcers must be chronic, or greater than 1 month in
duration to be included in the study. This is to capture
the most accurate data around DRFU, which have been
shown in the literature to take longer than 4 weeks to
heal [29]. Should a patient have an ulcer infection at the
time of recruitment, or develop an infection during the
trial they will receive appropriate antibiotic therapy and
will be able to continue in the trial. If appropriate in-
fection management is not commenced, irrespective of
the reasons, the patient will not be able to continue in
the trial.
Interventions
The two interventions are the two different methods of
ulcer debridement, LFUD and NSSD. The techniques for
both treatments are as described in Table 2.
Outcome measures
Primary outcome measure
The primary outcome measure for this study is the pro-
portion of ulcers healed over the six month follow-up
period. An ulcer is defined as healed in the presence of
intact skin, i.e. functional epithelial tissue [30], a total
surface area of 0 cm2 and restoration of functional and
anatomic continuity [31]. Ulcer healing status will be de-
termined by assessing the total ulcer area.
Ulcer surface area will be assessed using photographs
taken with a digital camera using a standard technique
Figure 1 Consort flow chart for the study.
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rent grid will be utilised over the printed photograph
and the total area calculated. Total surface area measure-
ments will be performed following each weekly treatment.
A research assistant blinded to the treatment allocationwill collect the data for the primary outcome measure.
This is to ensure the treating podiatrist is blinded to the
primary outcome during subsequent treatments.
The research assistant has been trained by the treating
podiatrist and given written instructions on how to use
Table 1 Participant inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
General: General:
≥ 30 years of age Patients taking immunosuppressive medications
Able to provide informed consent Known allergy to ulcer dressing products
Ulcers present for greater than 1 month Pre-existing ulcer pain preventing either type of debridement
Ulcers≥ 1 cm2
Vascular: Vascular:
Palpable pedal pulses OR biphasic or triphasic pedal pulses on
doppler OR toe pressure≥ 45 mmHg
Non-palpable pedal pulses OR monophasic pedal pulses on Doppler OR toe
pressure≤ 45 mmHg
Ulcer classification: Ulcer Classification:
Infected ulcers being appropriately managed Dry gangrenous ulcer
Those meeting The University of Texas Wound classification criteria [28]: Fungating ulcers
A1, A2, A3 (wounds of varying depth without infection or ischaemia) Malignant ulcers
B1, B2, B3 (wounds of varying depth with infection only) Those meeting the University of Texas wound classification criteria [28]:
A0, B0, C0, D0 (pre or post-ulcerative lesion with complete epithelialisation, with
or without infection and ischaemia)
C1, C2, C3 (wounds of varying depth with ischaemia only)
D1, D2, D3 (wound of varying depth with infection and ischaemia)
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termine reliability fifteen ulcers have been photographed
and both the research assistant and treating podiatrist
followed the same technique to calculate ulcer area.
Inter-rater measurement reliability between the treating
podiatrist and research assistant was found to have an
ICC of 0.91.
The ulcer depth will be measured by the treating po-
diatrist following each treatment, as depth cannot be
accurately assessed using a photograph. A disposable
measurement probe will be used to assess ulcer depth,
undermining, sinus or tracking.
A review of available literature around ulcer measure-
ment is scarce and of low evidence. The measurement
technique being used in this study, tracing and subse-
quent counting of centimetre squares, has a high inter-
rater and intra-rater reliability when compared to other
forms of ulcer measurement [32,33].Table 2 Standard step-by-step technique for LFUD and NSSD
LFUD
1) Constantly move the handpiece to prevent ultrasound burning tissue
2) Start debriding at the distal most aspect of the ulcer
3) Moving the handpiece left to right and from the distal to proximal aspect of
4) Once the entire ulcer surface has been debrided re-commence the same
from the distal most aspect of the ulcer
5) Continue until as much necrotic tissue has be removed as possible
6) Any peri-wound tissue that requires removal (i.e. callus, maceration) will oc
a scalpel. The wound base will not be debrided with the scalpel.A standard technique will be used for each method of
debridement and ulcer measurement ensuring consistency
(Tables 2 and 3).
Ulcers being treated in the intervention group will be
reviewed after six weeks of treatment. If LFUD is no
longer clinically indicated then treatment will be ceased
and the ulcers will then receive the control treatment
(NSSD). This change is to reflect the pragmatic nature
of the treatment and NSSD is considered standard ulcer
care. Clinical indications for ceasing LFUD treatment in-
clude pain, ulcer size and depth, clinical presentation
and no ulcer improvement.
Secondary outcome measures
Secondary outcome measures will include assessing ulcer
pain, quality of life and economic evaluation.
Ulcer pain will be measured weekly using a 100 mm
Visual Analogue Scale (VAS). Pain will be assessed priorNSSD
1) Start debriding at the distal most aspect of the ulcer
2) Moving scalpel proximally with each motion
the ulcer 3) Once the distal to proximal ulcer has been debrided then
debride from left side to right side
technique 4) Continue until as much necrotic tissue has been removed
as possible
5) Any peri-wound tissue that requires removal (i.e. callus,
maceration) will occur using a scalpel.
cur using
Table 3 Standard step-by-step technique for ulcer
measurement
Ulcer measurement
1) Ulcers that have tunnels or undermining will be marked on the skin
with a black marker
2) A white towel will be place under the foot to remove distracting
background elements
3) A disposable ruler will be labelled with participant number, wound
number, participant initials and the date
4) Position the disposable ruler alongside the ulcer and secure with
paper tape
5) Use macro camera setting with flash on, iso set to 200
6) Take photograph at a distance of 20 cm from the wound
7) Ulcer measurements will be conducted from print out using the
photograph (all photos will be printed as standard A4 size)
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of the scale (0 mm) will be labelled as no pain and the
far right end of the scale (100 mm) will be labelled as
worst pain imaginable. The VAS has been widely used
and has been shown to be a valid and reliable pain as-
sessment tool [34].
A health-related quality of life tool will be used to gain
perspective from each participant. This will be under-
taken at the initial treatment, at three months and again
at six months. If an ulcer heals prior to the end of the
six month study period the tool will be applied at that
point. The Eq 5D-5 L [35] assessment tool analyses five
health-related quality of life domains including mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. This tool has been widely used and has been
validated for use in patient groups with diabetes [36].
All data for the secondary outcome measures will be
collected by the treating podiatrist. No blinding will
occur for this data.
Each outcome measure and their time points of collec-
tion are summarised in Table 4.
Sample size
The sample size calculation for this study was based
upon the primary outcome comparison between groups
of the proportion of ulcers completely healed by the
six month follow-up. Previous research indicates that
nearly 25% of ulcers treated with NSSD healed within
six months [29], while another previous study found that
41% of ulcers treated with LFUD healed within three
months [24]. There is no six month data available for
the LFUD approach. A sample size of 147 ulcers per
group is required to achieve 80% power using a two-
tailed alpha of 0.05 to detect an absolute difference in
the proportion of ulcers healed of 0.16 (control = 0.25,
intervention = 0.41). To account for the intra-cluster cor-
relation of multiple ulcers being nested within a singleparticipant we adjust this for a design effect (1 + (n-1)*
ICC) using n = 3 ulcers per participant and ICC estimate
of 0.05; thus we require 161 ulcers per group. With an
average of 3 ulcers per participant we require 54 partici-
pants per group.
Randomisation
Randomisation will be undertaken using a permuted-
block randomisation approach. Randomisation blocks of
two, four or eight participants will be generated and ran-
domly selected and the resultant allocation order will be
entered into opaque, sealed envelopes. An investigator
not involved in recruitment or assessment (CW) will be
responsible for preparing the random allocation se-
quence and envelopes. The treatment conditions will be
provided as per the random allocation sequence follow-
ing completion of the initial assessment.
Once eligibility has been confirmed, a verbal explan-
ation of the project will be provided and the treating po-
diatrist will obtain written consent. All participants who
consent will have baseline assessments conducted prior
to randomisation, as outlined above. All ulcers (where
there is more than one per participant) will be num-
bered and documented according to anatomical location
prior to randomisation. Only the treatment condition
will be randomised, not each individual ulcer. Where
there is more than one ulcer, all will be treated with the
same method as per the randomisation process and in-
cluded in the study. Following randomisation the initial
treatment and measurements will commence as outlined
in Tables 2 and 3. All participants will receive treatment
and have their ulcers photographed and measured on a
weekly basis, as is standard podiatry practice at Monash
Health. Both groups will receive best practice ulcer man-
agement including appropriate ulcer dressings, pressure
off-loading and footwear provision as required.
Identifiable outcome data will be stored within the
participant’s health record. De-identifiable data will be
stored within a password-protected Excel spread sheet
within a secure hospital data management system as
per requirement of the Human Research Ethics Com-
mittee (HREC) for Monash Health. The primary inves-
tigator (LM) will be responsible for data entry and a
co-investigator (SB) will randomly audit information to
monitor data accuracy.
The trial will be managed by the research team and
led by the primary investigator (LM). The protocol
has undergone external review from the Lions John
Cockayne Research Fellowship committee and the re-
search team will give quarterly progress reports. An-
nual reports will also be required (including adverse
events) to the HREC of Monash Health. The research
team will meet on a monthly basis to address clinical
and data monitoring concerns.
Table 4 Outcome measures and timeframes
Data collection Measurement tool Data collected
method
Timeframe
Measurement of total ulcer area Centimetres squared; Research assistant Weekly: Post-treatment until
healed or at 6 months
Tracing from photographs and counting squares
Measurement of ulcer depth Centimetres; Treating podiatrist Weekly: post-treatment until
healed or at 6 months
Using sterile probe
Ulcer pain Visual analogue pain scale 100 mm Treating podiatrist Weekly: Pre-treatment, during
treatment, post-treatment
until healed or 6 months
Quality of life EQ-5D-5 L tool Participant questionnaire Initial treatment, at 3
months, at 6 months
Direct health costs
Consumable costs for treatments In dollars for each treatment Treating podiatrist Weekly, per participant until
healed or at 6 months
Medicare Benefit Scheme (MBS) MBS Care database, in dollars Extraction from MBS
database
End of project for each
participant from initial to
final treatment
Pharmaceutical Benefit Scheme (PBS) PBS Care database, in dollars Extraction from PBS
database
End of project for each
participant from initial to
final treatment
Inpatient data Monash Health: Hospitalisation costs Monash Health:
Admission duration, reason for admission, imaging and
interventions, obtained from the patient record and
from the Victorian Admitted Episodes Database
End of project
External organisation: End of
project
External organisation: Admission duration, reason for
admission, costs of any surgery for diabetes-related foot
ulcers will be estimated using WEISS funding
Hospital based services (outpatient
data)
Hours – time spent Treating podiatrist Weekly per participant until
healed or at 6 months
Medical imaging and pathology for
outpatients
Dollars – hospital based costs Treating podiatrist Monthly per participant until
healed or at 6 months
Community based services Number and cost of appointments Participant interview Monthly until healed or at
6 months
Private health appointments Number and cost of appointments, eligibility for private
health subsidies
Participant interview Monthly until healed or at
6 months
Royal District Nursing Service for ulcer
management
Frequency and cost of service Participant interview Monthly until healed or at
6 months
Ongoing ulcer care products Valued using market prices Participant interview Monthly until healed or at
6 months
Parking costs for appointments Dollars Participant interview Monthly until healed or at
6 months
Transportation costs to travel to
appointments
Estimated through Australian Tax Office car rate cents
per km
Participant interview Monthly until healed or at
6 months
Productivity costs
Time taken from work for participant
and/or any family member
Salary and hours taken from work Participant/family
interview
Monthly until healed or at
6 months
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The proportion of ulcers that are completely healed by the
six month follow-up will be compared between groups
using a logistic regression analysis approach with cluster-
ing of ulcer within participant. A member of the research
team (TH) who will be blinded to the allocation of the
participants will assess this.The rate of change in ulcer size (surface area, using
the post-debridement photo) will be compared between
groups using a linear mixed model analysis approach
where repeated assessments will be nested within ulcer,
and ulcers will be nested within participants. The groups
will be treated as a fixed factor while assessments, ulcer
and participants will be treated as random factors. All
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infected at baseline, as infection has been demonstra-
ted to delay healing [37] and HbA1c levels at baseline
as poor glycaemic control has been demonstrated to
delay healing [38].
A pre-planned interim analysis will be undertaken
after 70% of the planned sample size has been recruited.
This analysis will use all data available to that point in
time and examine the safety and efficacy outcomes from
the trial. A data analyst who is blinded to group alloca-
tion will be provided with the dataset and mock group
codes. The outcome of this analysis will be forwarded to
the remaining project investigators who will decide whe-
ther there is sufficient evidence to reject the null hypoth-
esis for the primary outcome. The assumptions underlying
the sample size calculation (e.g. ICC value) will also be ex-
amined at this point and revisions to the sample size will
be made if indicated.
Economic analysis
Cost effectiveness analysis
Direct and indirect health care costs will be collected at
regular intervals, as explained in Table 3.




¼ Incremental cost per additional ulcer healed
Cost utility analysis
A health related quality of life assessment obtained from
the EQ-5D-5 L tool will be converted to utility scores as
explained in Table 4. The economic evaluation will exa-
mine the cost per quality adjusted life year (QALY) gained
per patient provided with each intervention. QALY mea-
surements will use the EQ-5D-5 L utility-based cost-
effectiveness analysis. The formula to calculate QALYs
gained from the intervention will be:
CostLFUD–CostNSSD
QALYLFUD–QALYNSSD
¼ Incremental cost per QALY gained
Discussion
Diabetes-related foot ulceration is a significant medical
and social problem. Consensus among wound specialists
supports the importance of ulcer debridement to en-
courage ulcer healing. Despite this, there is a paucity of
evidence comparing different debridement techniques.
Whilst there is evidence available around the efficacy of
LFUD it has been limited. Furthermore, there is no ran-
domised controlled trial looking at the healing rates of
DRFU that undergo NSSD compared to LFUD.
This clinical trial will provide important information
in the field of ulcer management and provide a betterunderstanding of the efficacy of using NSSD treatment.
It will also provide health services with a better under-
standing of the financial impacts of both treatments.
Adverse events will be measured and recorded during
the study. The adverse events for both treatment groups
may include incidents such as sharps injuries to the par-
ticipant or treating podiatrist, development of ulcer in-
fection, hospital admission due to ulcer deterioration,
excess pain and bleeding from debridement at the ulcer
surface.
A limitation of this study is the non-consideration
given to nutritional status. Patient nutritional status has
potential to impact on ulcer healing, however outside of
a controlled inpatient environment it is difficult to en-
force a strict food regime. All patients will be encour-
aged to adhere to a suitable diet, however this will not
be controlled as part of this study.
A second limitation is that while a thorough assess-
ment of pain will be undertaken, this measure will only
focus on the individual ulcer pain before, during and
after debridement with either modality. Where partici-
pants have more than one ulcer in close proximity to an-
other ulcer the pain assessment may become difficult to
distinguish for each ulcer.
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